President Makes NCAB Appointments

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--President Clin-ton has reappointed Barbara K. Rimer, DrPH, to a second 2-year term as chair of the National Cancer Advisory Board (NCAB) and appointed Richard J. Boxer, MD, professor of family and community medicine, Medical College of Wisconsin, Milwaukee, to a full 6-year term. Dr. Boxer had served on the board for a year to complete the term of Paul Calabresi, MD, who resigned to join the President's Cancer Panel.

WASHINGTON--President Clin-ton has reappointed Barbara K. Rimer,DrPH, to a second 2-year term as chair of the National CancerAdvisory Board (NCAB) and appointed Richard J. Boxer, MD, professorof family and community medicine, Medical College of Wisconsin,Milwaukee, to a full 6-year term. Dr. Boxer had served on theboard for a year to complete the term of Paul Calabresi, MD, whoresigned to join the President's Cancer Panel.

The President also appointed four new members: Frederick P. Li,MD, head of the Division of Cancer Epidemiology, Dana-Farber CancerInstitute; Ivor Royston, MD, president and CEO of the Sidney KimmelCancer Center, San Diego; Ellen L. Stovall, executive directorof the National Coalition for Cancer Survivorship; and SandraMillon-Underwood, PhD, associate professor, University of Wisconsin,Milwaukee.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content